Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Michael W. Lower"'
Autor:
Ramon K. Kemp, Marian Iwamoto, Joshua Chen, Steven D. Young, Hedy Teppler, Robert A. Fromtling, Randi Y. Leavitt, Wei Xu, Robin Isaacs, Michael D. Miller, Daria J. Hazuda, Joseph P. Vacca, Bach-Yen Nguyen, Keith Gottesdiener, Michael W. Lower, Larissa Wenning, Michael Rowley, Peter Sklar
Publikováno v:
Annals of the New York Academy of Sciences. 1222:83-89
Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV-1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment-naive as well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe1348a4df68b1e28ec7d8980c82b000
https://doi.org/10.1111/j.1749-6632.2011.05972.x
https://doi.org/10.1111/j.1749-6632.2011.05972.x
Autor:
Bach-Yen T, Nguyen, Robin D, Isaacs, Hedy, Teppler, Randi Y, Leavitt, Peter, Sklar, Marian, Iwamoto, Larissa A, Wenning, Michael D, Miller, Joshua, Chen, Ramon, Kemp, Wei, Xu, Robert A, Fromtling, Joseph P, Vacca, Steven D, Young, Michael, Rowley, Michael W, Lower, Keith M, Gottesdiener, Daria J, Hazuda
Publikováno v:
Annals of the New York Academy of Sciences. 1222
Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV-1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment-naive as well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::40a8b1e3a06045aa88c5d0483d86acf3
https://pubmed.ncbi.nlm.nih.gov/21434946
https://pubmed.ncbi.nlm.nih.gov/21434946